Biotechnology articles from across Nature Portfolio

One year after the launch of ARPA-H, Nature talks to director Renee Wegrzyn about her vision for the agency.

Biochemist who invented recombinant DNA technology.

A bioengineered model incorporating a synthetic extracellular matrix recapitulates the lymphoid tumour microenvironment, making it a valuable tool for drug testing and designing personalized therapies.

Proteins have been developed that emit flashes of light in response to influxes of calcium ions into cells on millisecond timescales. Two sets of scientists discuss the legacy and future of these proteins.

Bacteria with a synthetic genome were engineered to alter the way that the DNA code instructs cells to make proteins. This ‘language barrier’ serves to isolate the cells genetically, and makes them immune to viral infection.

Findings from the DREAM-HF trial, the largest clinical trial of cell therapy in heart failure with reduced ejection fraction (HFrEF) to date, suggest that cardiac therapy with mesenchymal precursor cells might benefit patients with HFrEF, particularly those with inflammation.